期刊
ONCOIMMUNOLOGY
卷 1, 期 3, 页码 316-325出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.19127
关键词
oncoantigens; DNA vaccination; mammary cancer; immunotherapy; ErbB-2; in vivo electroporation
资金
- Italian Association for Cancer Research (AIRC) [IG 5377, 11675, IG 10353]
- Italian Ministry for the Universities and Research
- University of Torino
- Regione Piemonte (Piattaforma Innovativa)
- EU Consortium of Anticancer Antibody Development (EUCAAD) [200755]
- Regione Piemonte (ImmOnc)
The emerging evidence that DNA vaccines elicit a protective immune response in rodents, dogs and cancer patients, coupled with the US Food and Drug Administration (FDA) approval of an initial DNA vaccine to treat canine tumors is beginning to close the gap between the optimistic experimental data and their difficult application in a clinical setting. Here we review a series of conceptual and biotechnological advances that are working together to make DNA vaccines targeting molecules that play important roles during cancer progression (oncoantigens) a promise with near-term clinical impact.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据